Symbols / MLTX
MLTX Chart
About
MoonLake Immunotherapeutics, a clinical stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.29B |
| Enterprise Value | 856.95M | Income | -210.50M | Sales | — |
| Book/sh | 4.54 | Cash/sh | 5.97 | Dividend Yield | — |
| Payout | 0.00% | Employees | 100 | IPO | — |
| P/E | — | Forward P/E | -4.98 | PEG | — |
| P/S | — | P/B | 4.01 | P/C | — |
| EV/EBITDA | -3.78 | EV/Sales | — | Quick Ratio | 7.95 |
| Current Ratio | 8.50 | Debt/Eq | 26.01 | LT Debt/Eq | — |
| EPS (ttm) | -3.33 | EPS next Y | -3.65 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-02-26 | ROA | -30.72% |
| ROE | -54.33% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 70.85M |
| Shs Float | 31.35M | Short Float | 19.68% | Short Ratio | 2.06 |
| Short Interest | — | 52W High | 62.75 | 52W Low | 5.95 |
| Beta | 1.21 | Avg Volume | 2.25M | Volume | 1.39M |
| Target Price | $21.71 | Recom | Buy | Prev Close | $18.68 |
| Price | $18.20 | Change | -2.57% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$21.71
Mean price target
2. Current target
$18.20
Latest analyst target
3. DCF / Fair value
$-29.82
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$18.20
Low
$6.00
High
$35.00
Mean
$21.71
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-24 | main | Oppenheimer | Outperform → Outperform | $35 |
| 2026-02-23 | main | BTIG | Buy → Buy | $30 |
| 2026-02-23 | main | Needham | Buy → Buy | $25 |
| 2026-02-20 | main | RBC Capital | Sector Perform → Sector Perform | $12 |
| 2026-02-09 | reit | BTIG | Buy → Buy | $24 |
| 2026-02-03 | reit | HC Wainwright & Co. | Buy → Buy | $32 |
| 2026-01-15 | down | Goldman Sachs | Neutral → Sell | $10 |
| 2026-01-09 | reit | HC Wainwright & Co. | Buy → Buy | $32 |
| 2026-01-09 | up | BTIG | Neutral → Buy | $24 |
| 2025-11-21 | main | HC Wainwright & Co. | Buy → Buy | $26 |
| 2025-11-03 | up | HC Wainwright & Co. | Neutral → Buy | $30 |
| 2025-10-29 | down | Citigroup | Neutral → Sell | $5 |
| 2025-10-02 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2025-09-30 | main | Guggenheim | Buy → Buy | $20 |
| 2025-09-30 | main | Wedbush | Outperform → Outperform | $18 |
| 2025-09-30 | down | Citigroup | Buy → Neutral | $5 |
| 2025-09-30 | main | Needham | Buy → Buy | $20 |
| 2025-09-29 | down | RBC Capital | Outperform → Sector Perform | $10 |
| 2025-09-29 | down | BTIG | Buy → Neutral | $85 |
| 2025-08-06 | main | Goldman Sachs | Buy → Buy | $82 |
- Assessing MoonLake Immunotherapeutics (MLTX) Valuation After Positive Phase 2 S-OLARIS Trial Results - simplywall.st Wed, 25 Feb 2026 05
- MoonLake Immunotherapeutics (MLTX) Price Target Increased by 11.25% to 22.30 - Nasdaq ue, 24 Feb 2026 14
- MoonLake: Downgrade To Buy As Sonelokimab Still Has A BLA Shot On Goal (NASDAQ:MLTX) - Seeking Alpha ue, 24 Feb 2026 18
- New Analyst Forecast: $MLTX Given $30 Price Target - Quiver Quantitative ue, 24 Feb 2026 10
- MLTX: Oppenheimer Maintains 'Outperform' Rating, Raises Price Ta - GuruFocus ue, 24 Feb 2026 16
- MoonLake Immunotherapeutics (MLTX) Stock Analysis: A 25% Upside Potential in the Biotech Sector - DirectorsTalk Interviews ue, 17 Feb 2026 14
- MLTX Stock Heads Into Investor Day With FDA Momentum – What Traders Should Watch Next Week - Stocktwits hu, 19 Feb 2026 07
- Why Is MoonLake Immunotherapeutics Stock Trading Higher Today - MoonLake (NASDAQ:MLTX) - Benzinga Mon, 23 Feb 2026 14
- BioTech Breakout: MoonLake Up 30% On FDA Wins - MarketBeat ue, 03 Feb 2026 08
- MoonLake Immunotherapeutics (MLTX) Valuation Check After Mixed Share Price Performance - Yahoo Finance hu, 12 Feb 2026 08
- MoonLake Immunotherapeutics (MLTX) Gets a Hold from RBC Capital - The Globe and Mail Sat, 21 Feb 2026 12
- FDA opens door for new treatment option for painful HS skin disease - Stock Titan hu, 08 Jan 2026 08
- Dow, S&P 500, Nasdaq futures slip as Trump hikes tariffs, Iran tensions loom: Why MLTX, AG, VNDA, NFLX, VXUS are trending today - MSN Mon, 23 Feb 2026 04
- Citi Maintains MoonLake Immunotherapeutics(MLTX.US) With Sell Rating, Raises Target Price to $6 - 富途牛牛 ue, 24 Feb 2026 16
- MoonLake Immunotherapeutics (MLTX) Is Up 19.0% After Positive Phase 2 Axial Spondyloarthritis Data Release - Has The Bull Case Changed? - simplywall.st Mon, 23 Feb 2026 15
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 354296 | — | — | Stock Award(Grant) at price 0.00 per share. | BODENSTEDT MATTHIAS | Chief Financial Officer | — | 2026-01-07 00:00:00 | D |
| 1 | 196316 | nan | — | — | SANTOS DA SILVA JORGE | Chief Executive Officer | — | 2025-12-19 00:00:00 | D |
| 2 | 294473 | nan | — | — | BODENSTEDT MATTHIAS | Chief Financial Officer | — | 2025-12-19 00:00:00 | D |
| 3 | 35389 | nan | — | — | REICH KRISTIAN | Officer | — | 2025-12-19 00:00:00 | D |
| 4 | 200000 | 2974700.0 | — | Sale at price 14.49 - 15.08 per share. | SANTOS DA SILVA JORGE | Chief Executive Officer | — | 2025-12-09 00:00:00 | D |
| 5 | 202908 | 3012462.0 | — | Sale at price 14.43 - 15.08 per share. | REICH KRISTIAN | Officer | — | 2025-12-09 00:00:00 | D |
| 6 | 10870 | 98808.0 | — | Purchase at price 9.09 per share. | BODENSTEDT MATTHIAS | Chief Financial Officer | — | 2025-10-08 00:00:00 | D |
| 7 | 6499978 | 41618529.0 | — | Sale at price 6.24 - 6.96 per share. | CHEN BIHUA X. | Former | — | 2025-09-30 00:00:00 | I |
| 8 | 48978 | nan | — | — | REICH KRISTIAN | Officer | — | 2025-09-02 00:00:00 | D |
| 9 | 23500 | nan | — | — | MOUKHEIBIR CATHERINE | Director | — | 2025-07-03 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.09 | 0.09 | 0.09 |
| NormalizedEBITDA | -141.71M | -53.75M | -64.90M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -118.94M | -36.01M | -49.97M |
| ReconciledDepreciation | 1.38M | 370.32K | 164.78K |
| EBITDA | -141.71M | -53.75M | -64.90M |
| EBIT | -143.09M | -54.12M | -65.06M |
| NormalizedIncome | -118.94M | -36.01M | -49.97M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -118.94M | -36.01M | -49.97M |
| TotalExpenses | 143.09M | 54.12M | 65.06M |
| TotalOperatingIncomeAsReported | -143.09M | -54.12M | -65.06M |
| DilutedAverageShares | 62.87M | 49.12M | 38.98M |
| BasicAverageShares | 62.87M | 49.12M | 38.98M |
| DilutedEPS | -1.89 | -0.73 | -1.28 |
| BasicEPS | -1.89 | -0.73 | -1.28 |
| DilutedNIAvailtoComStockholders | -118.94M | -36.01M | -49.97M |
| NetIncomeCommonStockholders | -118.94M | -36.01M | -49.97M |
| NetIncome | -118.94M | -36.01M | -49.97M |
| MinorityInterests | 2.31M | 8.07M | 14.53M |
| NetIncomeIncludingNoncontrollingInterests | -121.24M | -44.08M | -64.51M |
| NetIncomeContinuousOperations | -121.24M | -44.08M | -64.51M |
| TaxProvision | 282.20K | 94.39K | 36.37K |
| PretaxIncome | -120.96M | -43.98M | -64.47M |
| OtherIncomeExpense | 22.13M | 10.14M | 591.73K |
| OtherNonOperatingIncomeExpenses | 22.13M | 10.14M | 591.73K |
| OperatingIncome | -143.09M | -54.12M | -65.06M |
| OperatingExpense | 143.09M | 54.12M | 65.06M |
| ResearchAndDevelopment | 112.77M | 31.80M | 42.05M |
| SellingGeneralAndAdministration | 30.32M | 22.32M | 23.01M |
| GeneralAndAdministrativeExpense | 30.32M | 22.32M | 23.01M |
| OtherGandA | 30.32M | 22.32M | 23.01M |
| TotalRevenue | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 63.08M | 60.47M | 38.98M | 36.93M |
| ShareIssued | 63.08M | 60.47M | 38.98M | 36.93M |
| NetDebt | 6.96M | |||
| TotalDebt | 2.83M | 3.70M | 282.58K | 15.00M |
| TangibleBookValue | 446.83M | 495.68M | 48.90M | -11.72M |
| InvestedCapital | 446.83M | 495.68M | 48.90M | 3.28M |
| WorkingCapital | 451.82M | 504.20M | 68.85M | -11.45M |
| NetTangibleAssets | 446.83M | 495.68M | 48.90M | -11.65M |
| CapitalLeaseObligations | 2.83M | 3.70M | 282.58K | 0.00 |
| CommonStockEquity | 446.83M | 495.68M | 48.90M | -11.72M |
| PreferredStockEquity | 72.47K | |||
| TotalCapitalization | 446.83M | 495.68M | 48.90M | -11.65M |
| TotalEquityGrossMinorityInterest | 453.39M | 513.49M | 68.77M | -11.65M |
| MinorityInterest | 6.57M | 17.82M | 19.87M | 0.00 |
| StockholdersEquity | 446.83M | 495.68M | 48.90M | -11.65M |
| GainsLossesNotAffectingRetainedEarnings | 5.00M | 2.36M | 350.95K | -168.18K |
| OtherEquityAdjustments | 5.00M | 2.36M | 350.95K | -168.18K |
| TreasuryStock | 0.00 | 6.20K | ||
| RetainedEarnings | -235.59M | -116.66M | -80.65M | -53.64M |
| AdditionalPaidInCapital | 677.41M | 609.97M | 129.19M | 42.06M |
| CapitalStock | 6.39K | 6.30K | 5.27K | 111.00K |
| CommonStock | 6.39K | 6.30K | 5.27K | 38.54K |
| PreferredStock | 0.00 | 0.00 | 72.47K | |
| TotalLiabilitiesNetMinorityInterest | 24.54M | 13.05M | 8.08M | 21.33M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 2.08M | 3.08M | 411.16K | 239.86K |
| EmployeeBenefits | 620.68K | 583.43K | 282.21K | 239.86K |
| NonCurrentPensionAndOtherPostretirementBenefitPlans | 620.68K | 583.43K | 282.21K | 239.86K |
| LongTermDebtAndCapitalLeaseObligation | 1.46M | 2.50M | 128.95K | 0.00 |
| LongTermCapitalLeaseObligation | 1.46M | 2.50M | 128.95K | 0.00 |
| CurrentLiabilities | 22.46M | 9.97M | 7.67M | 21.09M |
| CurrentDebtAndCapitalLeaseObligation | 1.37M | 1.20M | 153.63K | 15.00M |
| CurrentCapitalLeaseObligation | 1.37M | 1.20M | 153.63K | 0.00 |
| CurrentDebt | 15.00M | |||
| OtherCurrentBorrowings | 15.00M | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 4.24M | 2.78M | 1.11M | 1.42M |
| PayablesAndAccruedExpenses | 16.85M | 5.99M | 6.40M | 4.67M |
| CurrentAccruedExpenses | 7.22M | 3.78M | 6.04M | 3.04M |
| Payables | 9.63M | 2.21M | 364.80K | 1.63M |
| OtherPayable | 314.07K | 372.77K | 157.31K | 102.83K |
| TotalTaxPayable | 642.11K | 367.98K | 109.83K | 63.92K |
| AccountsPayable | 8.68M | 1.46M | 97.67K | 1.47M |
| TotalAssets | 477.93M | 526.54M | 76.84M | 9.68M |
| TotalNonCurrentAssets | 3.64M | 12.37M | 331.97K | 45.74K |
| NonCurrentPrepaidAssets | 0.00 | 8.42M | 0.00 | |
| NetPPE | 3.64M | 3.95M | 331.97K | 45.74K |
| GrossPPE | 3.64M | 3.95M | 331.97K | 45.74K |
| OtherProperties | 722.23K | 320.87K | 331.97K | 45.74K |
| BuildingsAndImprovements | 2.92M | 3.63M | 282.58K | 0.00 |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 474.29M | 514.17M | 76.51M | 9.64M |
| PrepaidAssets | 23.42M | 2.10M | 4.18M | 1.45M |
| Receivables | 2.84M | 1.06M | 217.13K | 148.77K |
| OtherReceivables | 2.84M | 1.06M | 217.13K | 148.77K |
| CashCashEquivalentsAndShortTermInvestments | 448.03M | 511.01M | 72.11M | 8.04M |
| OtherShortTermInvestments | 267.60M | 59.84M | 32.61M | 0.00 |
| CashAndCashEquivalents | 180.43M | 451.17M | 39.51M | 8.04M |
| CashFinancial | 8.04M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| FreeCashFlow | -117.11M | -43.06M | -55.91M |
| RepurchaseOfCapitalStock | -50.00 | 0.00 | 0.00 |
| RepaymentOfDebt | 0.00 | 0.00 | -15.00M |
| IssuanceOfDebt | 0.00 | ||
| IssuanceOfCapitalStock | 52.54M | 482.45M | 0.00 |
| CapitalExpenditure | -519.52K | -284.63K | -16.01K |
| IncomeTaxPaidSupplementalData | 147.29K | 41.71K | 4.31K |
| EndCashPosition | 180.43M | 451.17M | 39.51M |
| BeginningCashPosition | 451.17M | 39.51M | 8.04M |
| EffectOfExchangeRateChanges | 127.97K | -75.31K | 8.54K |
| ChangesInCash | -270.87M | 411.74M | 31.46M |
| FinancingCashFlow | 51.31M | 479.70M | 119.69M |
| CashFlowFromContinuingFinancingActivities | 51.31M | 479.70M | 119.69M |
| NetOtherFinancingCharges | -1.47M | -2.75M | 134.69M |
| ProceedsFromStockOptionExercised | 242.00K | 0.00 | 3.79K |
| NetPreferredStockIssuance | 0.00 | ||
| PreferredStockIssuance | 0.00 | ||
| NetCommonStockIssuance | 52.54M | 482.45M | 0.00 |
| CommonStockPayments | -50.00 | 0.00 | 0.00 |
| CommonStockIssuance | 52.54M | 482.45M | 0.00 |
| NetIssuancePaymentsOfDebt | 0.00 | 0.00 | -15.00M |
| NetShortTermDebtIssuance | 0.00 | ||
| ShortTermDebtIssuance | 0.00 | ||
| NetLongTermDebtIssuance | 0.00 | 0.00 | -15.00M |
| LongTermDebtPayments | 0.00 | 0.00 | -15.00M |
| InvestingCashFlow | -205.60M | -25.18M | -32.34M |
| CashFlowFromContinuingInvestingActivities | -205.60M | -25.18M | -32.34M |
| NetInvestmentPurchaseAndSale | -205.08M | -24.90M | -32.32M |
| SaleOfInvestment | 145.20M | 150.83M | 9.90M |
| PurchaseOfInvestment | -350.28M | -175.73M | -42.23M |
| NetPPEPurchaseAndSale | -519.52K | -284.63K | -16.01K |
| PurchaseOfPPE | -519.52K | -284.63K | -16.01K |
| OperatingCashFlow | -116.59M | -42.78M | -55.89M |
| CashFlowFromContinuingOperatingActivities | -116.59M | -42.78M | -55.89M |
| ChangeInWorkingCapital | -3.78M | -6.22M | -1.58M |
| ChangeInOtherWorkingCapital | -65.51K | ||
| ChangeInOtherCurrentLiabilities | -1.42M | -222.26K | -152.43K |
| ChangeInOtherCurrentAssets | -5.45K | -65.51K | 0.00 |
| ChangeInPayablesAndAccruedExpense | 12.32M | 1.26M | 1.37M |
| ChangeInAccruedExpense | 5.17M | -326.73K | 2.69M |
| ChangeInPayable | 7.15M | 1.58M | -1.31M |
| ChangeInPrepaidAssets | -12.89M | -6.35M | -2.73M |
| ChangeInReceivables | -1.79M | -839.73K | -68.36K |
| OtherNonCashItems | -227.01K | 127.60K | 68.45K |
| StockBasedCompensation | 7.28M | 7.11M | 9.65M |
| DepreciationAmortizationDepletion | 1.38M | 370.32K | 164.78K |
| DepreciationAndAmortization | 1.38M | 370.32K | 164.78K |
| Depreciation | 13.16K | 12.36K | |
| OperatingGainsLosses | 1.30K | -85.25K | 304.03K |
| PensionAndEmployeeBenefitExpense | 1.30K | -85.25K | 304.03K |
| NetIncomeFromContinuingOperations | -121.24M | -44.08M | -64.51M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for MLTX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|